Table 2.

Robust Opsonizing and Killing Function of Anti-Pneumococcal Capsular Polysaccharide-Specific IgG Antibodies in Infant Serum^a

	n = 11	n = 9		n = 11	n = 8
PCV13 Serotypes	HU Infants GMOI (95% CI)	HEU Infants GMOI (95% CI)	P Value	HU Infants GMC (95% CI)	HEU Infants GMC (95% CI)	P Value
4	52.70 (12.02–231.1)	69.57 (8.32–581.9)	.95	0.52 (.19–1.42)	0.9 (.2–4.03)	.66
6B	39.97 (7.27–219.6)	65.58 (5.72–752.1)	.76	0.39 (.2–.76)	0.55 (.17–1.83)	.75
14	169 (37.31–765.2)	223 (32.02–1553)	.82	0.46 (.2–1.08)	0.84 (.21–3.3)	.48
23F	48.82 (10.19–233.9)	78.70 (7.61–813.5)	.80	0.38 (.18–.79)	0.51 (.15–1.77)	.99
6A	46.37 (5.9–364.3)	74.07 (5.68–966.9)	.72	0.29 (.16–.52)	0.51 (.15–1.8)	.32
9V	65.79 (11.18–387.1)	82.85 (9.02–761.2)	.93	0.4 (.17–.91)	0.74 (.19–2.9)	.42
18C	55.35 (11.88 – 258)	70.12 (8.6–570.9)	.80	0.71 (.24–2.07)	1.17 (.18–7.48)	.99
19F	74.04 (14.81–370.2)	92.55 (11.48–746)	.93	0.65 (.3–1.42)	1.08 (.31–3.81)	.49
1	11.22 (6.65–18.92)	16.39 (6.35–42.26)	.49	2.19 (.96–5.02)	2.5 (.65–9.74)	.82
5	17.79 (6.98–45.31)	26.98 (7.97–91.28)	.44	0.53 (.23–1.21)	0.62 (.136–2.84)	.83
7F	142.4 (25.17–805.4)	117.4 (10.02–1376)	.87	0.63 (.21–1.86)	1.20 (.19–7.50)	.66
19A	23.52 (6.64–83.31)	47.49 (5.76–391.3)	.63	1.11 (.33–3.72)	2.31 (.4–13.37)	.50
3	22.37 (8.4–59.54)	24.31 (6.58–89.82)	.90	0.32 (.15–.7)	0.56 (2–1.63)	.48

Abbreviations: CI, confidence interval; GMC, geometric mean concentration; GMOI, geometric mean opsonophagocytic index; HEU, human immunodeficiency virus-exposed uninfected; HU, human immunodeficiency virus-unexposed uninfected; PCV13, pneumococcal conjugate vaccine 13.

^aThe GMOI and 95% CIs of results are reported for MOPA (HU n = 11, HEU n = 9); the serotype-specific IgG GMC (HU, n = 11; HEU, n = 8) for all PCV13 serotypes (1, 3, 4, 5, 6 A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are reported, and less than 8 was reported as no response.